What should you know about dual GIP and GLP-1 receptor agonists?

GIP and GLP-1 are gut hormones involved in signalling after meals. A dual agonist imitates both signals, which can reduce appetite, slow movement of food through the stomach and support glucose regulation. These effects can make a person feel full sooner, but the medicine is not suitable for everyone and does not replace an individual treatment plan. Nausea, vomiting, diarrhoea, constipation or reduced appetite may occur, particularly when treatment starts or the dose changes.

Use the prescribed product exactly as directed and do not share injection pens. Keep a record of doses and tell the prescriber about diabetes medicines, digestive problems, gallbladder disease, pregnancy plans or a history of pancreatitis. Eat slowly, choose fluids regularly and report ongoing vomiting because dehydration can become serious. Do not combine products or change the dose without advice. See [GLP-1 Receptor Agonist](/materials/glp-1-receptor-agonist/) for the medicine group and [Weight Loss Injections](/treatments/medical-management/weight-loss-injections/) for treatment context.

Get urgent help for severe or persistent abdominal pain, repeated vomiting, fainting, difficulty breathing, facial swelling or signs of a serious allergic reaction. If you have diabetes, seek prompt advice for confusion, sweating, shaking or unusual weakness, which may signal low blood glucose. Contact the prescriber about symptoms that prevent eating or drinking, severe constipation or pain after meals.

Ask what the medicine is intended to treat, how dose changes work, which symptoms are expected, how other medicines may interact, and what to do if an injection is missed.